To read the full story, subscribe or sign in.

Apollo signs near-$1B deal for Sunshine’s FGF21/GLP-1 injection

Nov. 19, 2024

Apollo Therapeutics Group Ltd. and Sunshine Lake Pharma Co. Ltd. inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshine’s dual fibroblast growth factor 21 (FGF21)/glucagon-like peptide-1 (GLP-1) receptor agonist currently in a phase II study for type 2 diabetes.

BioWorld Asia Deals and M&A Endocrine/metabolic Protein Asia-Pacific Europe China U.S.

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 12, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

KITE-753, a rapid manufactured CAR T therapy with superior antitumor efficacy and enhanced expansion in vivo

BioWorld Science

In a presentation at the recent American Society of Hematology meeting in San Diego, Kite Pharma Inc. reported preclinical data for KITE-753, an autologous rapid...

Keros stock wilts as it halts two dosing arms in hypertension study

BioWorld

After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension, the company’s stock crumpled after...

Upgrade your daily dose of biopharma and medtech news

Apollo signs near-$1B deal for Sunshine’s FGF21/GLP-1 injection